Rutgers researchers warn of rare sudden vision loss linked to Ozempic and Wegovy

Rutgers University researchers have warned that the GLP-1 drugs Ozempic and Wegovy, widely used for weight loss and diabetes treatment, may rarely cause serious sudden vision loss. The warning has raised concern among patients who rely on these medications for their health. The article also presents a first-person account from a writer with childhood amblyopia, or lazy eye, who describes how a VR training app called AmblyoPunch was used as a supplementary vision therapy tool alongside professional guidance. The author notes the app is not a cure or medical device but describes its gamified approach to retraining the brain and eyes. The piece is presented as a personal experience rather than a clinical study.